Catalent Inc (NYSE: CTLT) will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing...
(Reuters) – Catalent Inc plans a $100 million expansion of its plant in Anagni, Italy, where the contract drug manufacturer is currently filling millions of vials of COVID-19...
This is a reversal of the price action on the previous day, in which price moved up.The post Catalent Inc (CTLT): Price Down $-0.42 (-0.38)% Over Past Day, Up $0.25 (0.23)% Over...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Buy | Strong Buy |
| Technical Indicators | Buy | Strong Sell | Strong Sell | Strong Buy | Strong Buy |
| Summary | Neutral | Strong Sell | Strong Sell | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,680.70 | 2,684.70 | 2,646.00 | +20.4 | +0.77% | 1.52M | ||||
| 372.46 | 374.44 | 368.22 | +2.67 | +0.72% | 14.82M | ||||
| 191.76 | 198.57 | 190.88 | -14.77 | -7.15% | 54.22M | ||||
| 26.83 | 29.03 | 24.32 | +2.58 | +10.64% | 31.17M | ||||
| 192.94 | 194.42 | 189.14 | -2.64 | -1.35% | 20.33M | ||||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | ||||
| 162.37 | 168.39 | 162.05 | -10.29 | -5.96% | 10.16M | ||||
| 16.40 | 16.58 | 16.36 | -0.11 | -0.67% | 341.22K | ||||
| 6.18 | 6.28 | 6.11 | +0.060 | +0.98% | 9.90M | ||||
| 59.98 | 60.26 | 59.58 | +0.58 | +0.98% | 41.10K | ||||
| 21.31 | 21.63 | 20.76 | +0.50 | +2.40% | 5.85M | ||||
| 1.07 | 1.08 | 1.03 | +0.0400 | +3.88% | 4.80M | ||||
| 61.12 | 61.88 | 59.66 | +1.17 | +1.95% | 1.32M | ||||
| 13.12 | 13.33 | 12.86 | +0.29 | +2.26% | 2.77M | ||||
| 0.5936 | 0.00 | 0.00 | +0.0035 | +0.59% | 1.02M |
Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
